Brief Summary

The REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study is the largest prospective multicenter data base for CIN flowing coronary angiography (CAG) or percutaneous coronary intervention (PCI). The REICIN study has the potential to characterize contemporary CIN incidence, modified risk factors and prognosis, so that to identify strategiaes to reduce risk of CIN following CAG/PCI.

Trial Health

At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date

Enrollment

5,000

participants targeted

Target at P75+ for all trials

Timeline

Completed

Started Jan 2013

Longer than P75 for all trials

Geographic Reach

1 country

12 active sites

Status

unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

5.8 years study duration

First Submitted

Initial submission to the registry

July 25, 2011

Completed

1 day until next milestone

First Posted

Study publicly available on registry

July 26, 2011

Completed

1.4 years until next milestone

Study Start

First participant enrolled

January 1, 2013

Completed

3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed

2.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed

Last Updated

August 3, 2018

Status Verified

August 1, 2018

Enrollment Period

3.1 years

First QC Date

July 25, 2011

Last Update Submit

August 1, 2018

Conditions

Contrast Induced Nephropathy

Keywords

contrast-induced nephropathycontrast mediumcreatinine clearancecoronary angiographydiabeteschronic kidney diseasepredictive

Outcome Measures

Primary Outcomes (1)

contrast-induced nephropathy
Contrast-Induced Nephropathy was defined as a ≥ 0.5 mg/dL or 25% increase in serum creatinine from baseline during the first 48 to 72 hours after the procedure.
48-72 h

Secondary Outcomes (6)

contrast-induced acute kidney injury (CI-AKI0.3)
48h
Cystatin C based CI-AKI (CI-AKIcyc)
24-48h
The change of eGFR, calculate based on CrCl and serum cystatin C
48-72 h
Persistent CI-AKI (CI-AKIp)
3 months
In-hospital major adverse cardiovascular and clinical events
In-hospital
+1 more secondary outcomes

Study Arms (1)

coronary angiography

We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

We reviewed all consecutive patients who were undergoing coronary angiography

You may qualify if:

Patients referred to CAG or PCI;
Age ≥ 18 years
Submit informed consent and adhere to the study protocol

You may not qualify if:

Fail to undergo CAG/PCI or die during the procedure；
End-stage renal diseases or renal replacement；
Pre-procedural unstable renal funciton (acute increase in serum creatinine more than 0.5mg/ml in the past 24 h)；
Intravascular administration of a contrast medium within the previous 48 hours；
Allergic to contrast medium;
Pregnancy, lactation or malignant tumoror life expectancy\< 1 year;
The use of renal toxicity drugs (non-steroidal anti-inflammatory drugs, aminoglycoside drugs, cyclosporine, cisplatin etc) within 48 h before cardiac catheter surgery and the whole process of the research;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Guangdong Provincial People's Hospitallead
First Affiliated Hospital, Sun Yat-Sen Universitycollaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universitycollaborator
Nanfang Hospital, Southern Medical Universitycollaborator
Guangzhou General Hospital of Guangzhou Military Commandcollaborator
Guangdong Medical Collegecollaborator
Dongguan Kanghua Hospitalcollaborator
Dongguan People's Hospitalcollaborator
Maoming People's Hospitalcollaborator
Futian People's Hospitalcollaborator
Longyan City First Hospitalcollaborator
First People's Hospital of Kashgarcollaborator

Study Sites (12)

Kaihong Chen

Longyan, Fujian, China

Location

Guoliang Jia

Dongguan, Guangdong, 510000, China

Location

Jianfeng Ye

Dongguan, Guangdong, 510000, China

Location

Jian Qiu